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Inflammation is central to the pathology of periodontitis 
and peri- implantitis following colonization with Gram- 
negative bacteria contained in the dental plaque biofilm, 
such as Porphyromonas gingivalis and Fusobacterium nu-
cleatum [1]. The inflammatory response is characterized by 
the recruitment of leukocytes, vascular dilation, increased 
blood flow, and enhanced permeability of blood capillaries. 
Typically, the innate immune system induces an inflamma-
tory response capable of eradicating bacteria and returning 
tissue homeostasis. Failure of the innate immune system to 
eliminate inflammation and clear immune cells can lead to 
chronic inflammation, which is characterized by a prolonged 
and persistent inflammatory response to external stimuli, 
like bacterial components such lipopolysaccharide (LPS) 
[2]. During chronic inflammation, inflammatory mediators, 
such as cytokines, chemokines, and prostaglandins, amplify 
the inflammatory response by recruiting more leukocytes 
and platelets to the site of infection [3, 4]. Elevated levels of 
inflammatory mediators, such as prostaglandin E2 (PGE2), 
closely correlate with the disease severity in patients with 
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Abstract
Scaling and root planning is a key element in the mechanical therapy used for the 
eradication of biofilm, which is the major etiological factor for periodontitis and 
peri- implantitis. However, periodontitis is also a host mediated disease, therefore, re-
moval of the biofilm without adjunctive therapy may not achieve the desired clinical 
outcome due to persistent activation of the innate and adaptive immune cells. Most 
recently, even the resident cells of the periodontium, including periodontal ligament 
fibroblasts, have been shown to produce several inflammatory factors in response to 
bacterial challenge. With increased understanding of the pathophysiology of perio-
dontitis, more research is focusing on opposing excessive inflammation with special-
ized pro- resolving mediators (SPMs). This review article covers the major limitations 
of current standards of care for periodontitis and peri- implantitis, and it highlights 
recent advances and prospects of SPMs in the context of tissue reconstruction and 
regeneration. Here, we focus primarily on the role of SPMs in restoring tissue homeo-
stasis after periodontal infection.
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periodontitis and peri- implantitis [5]. Therefore, the primary 
objective of periodontal therapy is the regulation of the host 
defense mechanisms underlying chronic inflammation.
Current non- surgical treatment strategies for periodonti-
tis and peri- implantitis patients present several challenges, 
including inability to control inflammation, high cost, and 
increasing threat of antibacterial resistance [6]. Moreover, 
traditional management of these diseases has not changed ap-
propriately over the last decades despite an increased under-
standing of their pathophysiology [7]. Typically, treatment 
consists of scaling and root planning (SRP) and in ‘refrac-
tory cases’ (i.e., cases that do not respond to treatment) or 
‘aggressive’ forms (i.e., fast progressive cases with severe 
damage) of the disease, adjunctive therapy is commonly 
used, such as the administration of broad- spectrum antibiot-
ics (e.g., amoxicillin and metronidazole or doxycycline) [8]. 
However, repetitive use of antibiotics can lead to bacterial 
resistance and notable side effects, such as nausea, diarrhea, 
and hypertension [9]. Furthermore, glucocorticoids, such as 
dexamethasone, are commonly prescribed to manage inflam-
mation associated with chronic inflammatory diseases due 
to their immunosuppressive actions on the immune system, 
such as the inhibition of interleukin (IL)- 6, 8 and tumor ne-
crosis factor α (TNFα) [10]. Glucocorticoids are, however, 
limited by their anti- proliferative actions on the periodon-
tium, resulting in attachment loss, disruption of transseptal 
fibers, and down- migration of the epithelium, as well as bone 
loss, which can negatively impact implant osseointegration 
[11]. Nonsteroidal anti- inflammatory drugs (NSAIDs; e.g., 
ibuprofen, aspirin, flurbiprofen, indomethacin, naproxen) are 
widely prescribed in dentistry to reduce inflammation and 
manage pain associated with invasive dental procedures. 
NSAIDSs work by inhibiting cyclooxygenase (COX) en-
zymes and thereby limit synthesis of prostaglandins, such 
as PGE2 and PGI2 [12,  13]. NSAIDs can produce several 
beneficial effects in periodontitis and peri- implantitis pa-
tients, including periodontal and implant wound healing [14]. 
However, NSAIDs can take a long time to produce a thera-
peutic response (years rather than months) and are associated 
with undesirable effects that include gastrointestinal prob-
lems and hemorrhage (due to decreased platelet aggregation), 
as well as renal and hepatic dysfunction [12]. Additionally, 
patients on long- term NSAIDs also run the risk of acceler-
ated bone loss if they cease taking them. Hence, conventional 
periodontal therapy can be insufficient for preventing disease 
progression and eliminating subgingival infection without 
eliciting adverse side effects.
Alternatively, specialized pro- resolving mediators (SPMs) 
are endogenous cell- signaling molecules released during in-
flammation to promote resolution of inflammation, which 
is a coordinated response aimed at restoring tissue integrity 
and function [15– 18]. Despite the cellular and molecular 
mechanisms of inflammation being extensively described in 
the literature for periodontitis and peri- implantitis [19– 21], 
a comprehensive review on the effect of SPMs on immune 
cells (innate and adaptive) and periodontal cells is lacking. 
In this review, we consider the use of SPMs as a new thera-
peutic strategy to replace antibiotics and mitigate the growing 
problem of antibiotic resistance. Here, the function of SPMs 
is addressed, with a focus on how SPMs affect the innate and 
adaptive immune system cells. Finally, we highlight recent 
discoveries regarding the anti- inflammatory effects of SPMs 
in harnessing endogenous resolution responses in periodon-
tal cells.
MATERIAL AND METHODS
This narrative review is based on preclinical and clinical 
studies in English without restrictions regarding year of pub-
lication. The review focused on the following questions:
(i) What is the role of inflammation in periodontal and peri- 
implant tissue breakdown?
(ii) Which cell types of the innate and adaptive immune sys-
tem (as well as cells of the periodontium) are involved in 
mediating periodontal tissue destruction?
(iii) What is the therapeutic application of SPMs in periodon-
tal tissue regeneration?
The electronic databases Medline (via PubMed), Scopus, 
and Embase were searched for eligible studies in the field 
of periodontology, implantology, and immunology. The 
main search terms were ‘pro- resolving agents,’ ‘periodon-
titis,’ ‘peri- implantitis,’ ‘resolution,’ and ‘inflammation.’ 
Subsequently, the title and abstract of obtained articles were 
screened for relevancy to the research criteria. The inclusion 
criteria consisted of the following: (i) full text original studies 
in the English language; (ii) research articles demonstrating 
the effect(s) of SPMs in in vitro and in vivo model systems; 
and (iii) experimental studies involving the clinical periodon-
titis or peri- implantitis situation. The references contained in 
original articles and review articles were also searched for 
possible inclusion. No further inclusion criteria were applied.
Pathogenesis of periodontitis and  
peri- implantitis
Periodontitis
Periodontitis is characterized by bacterial infection leading 
to inflammation of the periodontium, which makes up the 
specialized tissues that surround and support the teeth [1]. 
Periodontitis develops from a superficial reversible type of 
inflammation, gingivitis, that develops in the gingiva (or 
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gums). In gingivitis, regeneration processes are activated in 
such a way that complete replacement with new cells usually 
occurs without any permanent tissue damage [6]. In perio-
dontitis, however, healing is overridden by irreversible scar-
ring, fibrosis, and destruction of the cellular matrix, which 
usually requires lifelong treatment [2]. Inflammation is cen-
tral to the pathology of diseases of the periodontium and a 
thorough understanding is key to the development of novel 
treatment strategies that can promote wound healing and re-
store tissue function.
Peri- implantitis
Dental implants were first introduced in the 1950s, and since 
the 1980s they have become increasingly popular for replacing 
missing teeth and enhancing masticatory function [22]. The 
prevalence of dental implants in the United States is estimated 
to increase from 5.7% to 17% per year by 2026 [23]. With in-
creasing reliance on dental implants, complications and dental 
implant failures have become increasingly problematic due to 
the aging population and increasing cost of treatment [24]. The 
clinical signs of peri- implantitis consist of bleeding on probing 
(BOP), redness, edema, and bone loss [22]. There are several 
risk factors for dental implant failures, including the patient's 
medical history (e.g., diabetes, periodontitis, and other sys-
temic disease), lifestyle (e.g., smoking, and alcohol consump-
tion), and implant surface characteristics (e.g., smooth or 
rough) [22]. For instance, Berglundh et al. [25] showed that 
implants with a rough surface morphology elicited more bone 
loss compared with smooth- surfaced implants. Furthermore, 
excessive biomechanical forces can lead to microfractures 
in the bone around the implants, which can result in implant 
failure [26]. Still, a main reason for dental implant failure is 
the consistent exposure to the oral microflora, which includes 
oral bacteria that can easily colonize the dental implant sur-
face and form a pathogenic biofilm [27]. A pathogenic biofilm 
can result in mucosal inflammation of the soft tissue (or peri- 
implant mucositis), alveolar bone resorption, and eventually 
implant loss over time [22]. Although both periodontitis and 
peri- implantitis have similar pathologies, there are key histo-
pathological differences that discern them.
Histopathological differences in 
periodontitis and peri- implantitis
Periodontitis and peri- implantitis are results of unresolved 
inflammation occurring in response to the pathogenic bacte-
rial biofilm residing on the tooth (or implant) surface (Figure 
1) [19]. Despite both conditions being inflammatory in na-
ture, results from experimental animal studies indicate key 
histopathological differences that could explain variations 
in disease onset and progression [28]. Earlier experiments in 
large animals, such as dogs and monkeys, have identified dif-
ferences between these two inflammatory lesions [29– 31]. In 
these studies, experimental periodontitis and peri- implantitis 
were established by placing ligatures around the neck of the 
tooth (or implant), which allowed subgingival biofilm for-
mation. Characterization of human biopsy samples revealed 
several quantitative immunological differences between peri-
odontitis and peri- implantitis lesions [19]. For instance, his-
tological analysis of peri- implantitis lesions showed a more 
pronounced inflammatory cell infiltration compared to peri-
odontitis lesions [32, 33]. Bullon et al. [34] and Gualini & 
Berglundh [21] reported higher levels of macrophages, plasma 
cells, lymphocytes, T cells, and B cells in human periodonti-
tis and peri- implantitis lesions compared with healthy tissues. 
Moreover, the levels of T cells were significantly higher in 
human peri- implantitis patients compared with periodontitis 
patients, and this has been shown to mediate IL- 17- induced 
osteoclastogenesis and bone resorption via nuclear factor- κB 
ligand (RANKL) activation [35, 36]. Interestingly, Konttinen 
et al. [37] showed that peri- implantitis lesions contained more 
cells positive for IL- 1α, IL- 6, and TNF- α compared with peri-
odontitis lesions. Generally, it was found that peri- implantitis 
lesions contained a higher number of cells positive for pro- 
inflammatory cytokines and chemokines (IL- 1β, IL- 6) than 
periodontitis lesions and healthy tissues [38].
Furthermore, histological examination of the two le-
sions showed that tissue destruction and bone loss was more 
pronounced surrounding implants compared with teeth 
[30, 39, 40]. Additionally, peri- implantitis lesions were larger, 
extended closer to the alveolar bone crest, and contained more 
osteoclasts compared to periodontitis lesions [20]. The more 
pronounced tissue destruction observed in peri- implantitis 
lesions is attributed to a combination of biomechanical over-
load and the presence of more pathogenic bacteria [26]. 
F I G U R E  1  Periodontal and peri- implant tissues in health (left) 
and disease (right). In the diseased conditions, a biofilm (in yellow) 
develops on the tooth or implant surface resulting in inflammation and 
destruction of the supporting tissues. Unresolved inflammation leads to 
deep periodontal/peri- implant pockets and an increase in immune cell 
infiltration at the inflammatory lesion. [Colour figure can be viewed at 
wileyonlinelibrary.com]
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Additionally, the differences in the collagen fiber orientation 
(parallel to implant and perpendicular with teeth) and a larger 
vasculature density may explain the faster pattern of destruc-
tion with peri- implantitis than with periodontitis lesions [28]. 
Overall, there are quantitative histopathological differences 
between the two lesions, and these differences have indicated 
a more pronounced inflammatory response in peri- implantitis 
compared with periodontitis lesions.
Specialized pro- resolving mediators resolve 
inflammation
Chronic unresolved inflammation in periodontal and peri- 
implant disease can lead to irreversible tissue destruction. 
Over the past decade, there has been increasing interest in 
using SPMs for the resolution of inflammation for several 
inflammatory diseases, including periodontitis and peri- 
implantitis. Recent studies have confirmed that resolution of 
inflammation is an active process rather than a passive one, 
and this process is normally maintained by endogenous pro- 
resolution mediators (or agonists) [41]. The discovery of 
SPMs, such as lipoxins, resolvins, and protectins, have cre-
ated new possibilities for development of therapies targeting 
resolution pathways to terminate inflammation and facilitate 
the return of inflamed tissues to homeostasis. Resolution of 
inflammation is a coordinated process that provides ‘stop sig-
nals’ to terminate and eliminate infiltration of immune cells to 
the inflammation site. SPMs are readily generated by cells to 
limit leukocyte recruitment, chemotaxis to inflamed sites, and 
the progression of acute inflammation to chronic inflamma-
tion. Additionally, SPMs promote the clearance of leukocytes, 
fibrin, and exudates, which restore damaged tissue function. 
In general, SPMs work by activating repair mechanisms and 
returning inflamed (or diseased) tissue back to normal physi-
ological function (or homeostasis). However, relatively little 
is known regarding the effect of SPMs on the innate and adap-
tive immune cells, as well as on cells of the periodontium.
Cellular targets for specialized  
pro- resolving mediators
SPMs limit inflammation by utilizing pro- resolution pathways 
to promote resolution of inflammation and return tissue homeo-
stasis (Table 1). SPMs induce effects similar to those of gluco-
corticoids and NSAIDs without producing notable side effects, 
such as liver and kidney damage [16]. The following sections 
will focus on the molecular background behind the therapeu-
tic mechanisms involved in the termination of inflammation 
by SPMs. Additionally, the properties and function of differ-
ent immune (acute and adaptive) and periodontium cells in tis-
sue inflammation and bone resorption will be discussed in the 
context of periodontitis and peri- implantitis. Finally, the effect 
of SPMs on inflammation will be discussed for each cell type.
Innate immune cells
Polymorphonuclear neutrophils
Polymorphonuclear neutrophils (PMNs) are the most abun-
dant white blood cells and the first line of defense recruited 
by the innate immune system in response to bacterial invasion 
(Figure 2) [42, 43]. During infection, circulating PMNs in the 
blood stream respond to chemoattractants (e.g., cytokines, 
chemokines, and leukotrienes) and adhesion molecules (e.g., 
selectins, integrins) to accumulate at the site of inflammation. 
PMNs activate several anti- microbial functions, including 
phagocytosis, the release of soluble anti- microbials, and the 
generation of neutrophil extracellular nets and myeloperoxi-
dase. Myeloperoxidase secreted from the azurophil granules 
of PMNs serves two main functions: (i) eradicate pathogens 
by forming highly reactive halide- derived oxidants, and (ii) 
prolong the life span of PMNs by promoting powerful anti- 
apoptotic signals [44]. Delayed PMN clearance is a key fac-
tor that promotes tissue destruction in several inflammatory 
diseases, including acute respiratory syndrome, certain types 
of cancer, and periodontal disease [45, 46]. Hence, the clear-
ance of PMNs from the site of inflammation by phagocytes 
(e.g., monocytes and macrophages) is crucial to limiting in-
flammation and, therefore, preventing tissue damage [47].
Since PMNs have been implicated in inflammatory dis-
eases, controlling PMN infiltration has been a major phar-
maceutical target for treating inflammation- induced tissue 
destruction. To assess the effect of SPMs on PMN infiltration, 
fluorometric measurements of cytosolic calcium (Ca2+) were 
carried out in vitro using human PMNs obtained from healthy 
volunteers [48]. In that study, lipoxin intermediate (leukotriene 
A4) was shown to promote migration of PMNs by increasing 
cytosolic Ca2+ levels via ALX/FPR2 receptor- mediated inter-
actions. Higher cytosolic Ca2+ concentrations correlated with 
increased transendothelial migration of PMNs from assembly 
of cytoskeletal elements into pseudopods, leading to the clear-
ance of PMNs from the inflammation site [49]. In addition to 
promoting clearance, lipoxin induced the activation of apop-
totic signals in PMNs by suppressing apoptosis- promoting 
proteins, such as serum amyloid A [50]. Moreover, studies 
have shown that lipoxin prevents tissue injury by inhibiting the 
formation of reactive nitrogen intermediates, such as peroxyni-
trite (ONOO) [51, 52]. In addition, lipoxin has been shown to 
inhibit the accumulation of nuclear factor κB (NF- κB) and ac-
tivator protein- 1 (AP- 1), and this decreased the production of 
the inflammatory cytokines that normally promote PMN ac-
cumulation and activation (e.g., IL- 8). Furthermore, resolvins 
have also been shown to inhibit PMN migration, infiltration, 
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T A B L E  1  Summary of the main effects and concentration of specialized pro- resolving mediators.
SPM Concentration of SPM Cell/animal type Main effect mediated by SPM Ref.
LXA4 In vitro: 500 nM Human leukocytes Inhibited LPS- stimulated peroxynitrite formation, 
NF- κB and AP−1 activation, and IL−8 gene 
expression
[15]




Suppressed osteoclastogenesis and prevented 
ovariectomy- induced bone loss
[16]
LXA4 In vitro: 1−100 nM Human stem cells of the apical 
papilla
Enhanced proliferation, migration, and promoted 
wound healing capacity; inhibited secretion of 
cytokines and chemokines in a dose- dependent 
manner, including IL−6, IL−8, CXCL10, 
CCL2, CCL11, VEGF
[17]
LXA4 In vitro: 10−100 nM Murine RAW264.7 and MC3 T3- 
E1 osteoblasts co- culture
Inhibited secretion of pro- inflammatory cytokines, 
including TNFα, IL−1β, PGE2 and GM- CSF
[18]




Enhanced resolution of inflammation by 
overriding anti- apoptosis signals
[50]
LXA4 In vitro: 100– 1000 nM Human & murine macrophages Impaired apoptosis signaling in macrophages via 
activation of PI3 K- Akt signaling
[54]
LXA4 In vitro: 10 nM Human monocytes and 
polymorphonuclear 
neutrophil (PMN)
Promoted phagocytosis of apoptotic PMNs by 
monocyte derived macrophages
[63]
PD1 In vitro: n/a
In vivo: 100 ng per animal
Human PBMC and T Cells
Mice
Inhibited T- cell migration and production of 
TNFα; promoted apoptosis of T cells
[81]




In vivo: 1 μg per mouse
Human peripheral B cells
Mice
Inhibited B cell production of antibodies (IgM and 
IgG) and proliferation
[93]
RvD1 In vitro: 0.1– 10 ng/ml Human periodontal ligament 
fibroblasts and peripheral 
blood mononuclear cells
Decreased production of PGE2; decreased 
cytokine induced production of PGE2; 
upregulated LXA4 production in both cell types
[95]
RvE1 In vivo: 8 μl per animal Rabbits Induced complete resolution of inflammation of 
the soft and hard tissues
[106]
RvD1 In vitro: 1000 nM Human gingival fibroblasts Reduced the expression of IL−6 and MCP−1, 
GRO, and marginally increased the production 
of TGF- β1
[110]
RvE1 In vitro: 1– 3 ng/ml Murine osteoclasts Reduced osteoclast differentiation and bone 
resorption activity
[121]
RvE1 In vitro: 10 nM Murine osteoclasts Reduced osteoclast formation [122]
RvD1 In vitro: 100– 500 nM
In vivo: 500– 1000 ng
Human RAW264.7 cells
Mice
Prevented bone resorption in vitro and in vivo [127]
RvE1 In vitro: 100 nM Murine osteoclasts Decreased production of RANKL and maintained 
a RANKL/OPG ratio more favorable for bone 
formation; significantly decreased osteoclast 
differentiation and bone resorption
[136]
RvE1 In vitro: 50– 200 nM Murine RAW264.7 cells Inhibited osteoclatogensis and bone resorption 
by suppressing IL−17 induced RANKL 
expression in osteoclasts
[137]
Abbreviations: AP- 1, activator protein 1; CCL, C- C motif chemokine ligand; CXCL, C- X- C motif chemokine ligand 10; GM- CSF, Granulocyte- macrophage 
colony- stimulating factor; GRO, growth- regulated oncogene; IFNγ, Interferon gamma; IgG, Immunoglobulin G; IgM, Immunoglobulin M; IL, interleukin; LPS, 
lipopolysaccharide; LXA4, lipoxin A4; NAB1, NGFI- A Binding Protein 1; NF- κB, Nuclear factor kappa B; OPG, osteoprotegerin; PBMC, peripheral blood 
mononuclear cells; PD1, Protectin D1; PGE2, prostaglandin E2; PI3 K- Akt, phosphatidylinositol- 4, 5- bisphosphate 3- kinase; RANKL, Receptor activator of nuclear 
factor kappa- Β ligand; RvD1, Resolvin D1; RvE1, MCP- 1, monocyte chemoattractant protein 1; RvE1, Resolvin E1; SPM, Specialized pro- resolving mediator; TGF- 
β1, transforming growth factor- β1; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.
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and accumulation at the inflammation site [48,  53]. To this 
end, inhibition of PMN recruitment by SPMs is vital for pre-
venting the progression of inflammation.
Macrophages
Macrophages contribute to the clearance of pathogens and 
cellular debris from the inflammation site [54]. Macrophages 
can be polarized into two phenotypes depending on their 
microenvironment: the pro- inflammatory (M1) or the anti- 
inflammatory (M2) subtypes. M1- type macrophage polari-
zation occurs in response to production of pro- inflammatory 
cytokines, such interferon gamma (IFN- γ), or by interactions 
with bacterial LPS. M1- type macrophages exhibit an inflam-
matory phenotype, which is associated with higher levels of 
pro- inflammatory mediators, such as IL- 1β, IL- 6, TNFα, and 
nitric oxide (NO) [55]. In addition, M1- type macrophages 
contribute to the elimination of pathogenic microorganisms 
by phagocytosis of pathogenic microorganisms. However, 
persistent activation of pro- inflammatory M1 macrophages 
produces excessive release of the pro- inflammatory media-
tors that contribute to chronic inflammation and correlate with 
tissue injury [56]. In contrast to M1- macrophages, M2- primed 
macrophages secrete anti- inflammatory cytokines, such as 
IL- 4 and IL- 3, both of which have several important functions 
required for the resolution of inflammation and wound- healing 
[57]. Among these functions, M2- primed macrophages also 
phagocytose apoptotic PMNs and pathogens, which facilitates 
the return of tissue homeostasis [58]. The clearance of apop-
totic PMNs is vital for redirecting polarization of macrophages 
from the M1 to the M2 phenotype [59]. Hence, macrophage 
polarization in gingival tissue is an important disease indicator 
and a critical therapeutic target for controlling disease progres-
sion in periodontal inflammation [60].
Lipoxins have been shown to promote resolution of the 
inflammation in a concentration- dependent manner by delay-
ing apoptosis of macrophages and enhancing phagocytosis of 
PMNs [61]. Furthermore, lipoxins have been shown to pro-
long the survival of macrophages by activating anti- apoptotic 
signaling pathways, including phosphatidylinositol- 4, 
5- bisphosphate 3- kinase (PI3 K- Akt) and extracellular signal- 
regulated kinase (ERK) [54]. The activation of PI3 K- Akt and 
ERK signaling pathways increases the production of anti- 
apoptotic mediators, such as myeloid cell leukemia 1 (Mcl- 1), 
and leads to the suppression of pro- apoptotic mediators, such 
F I G U R E  2  The role of specialized pro- resolving mediators (SPMs) in the inhibition of polymorphonucleated neutrophils (PMNs). (1) In the 
lower right of the figure, microbial invasion injury induces chemotactic signals, including leukotriene B4 (LTB4), reactive oxygen species (ROS), 
cytokines, and hydrolytic enzymes, which activate PMNs chemotaxis to the site of injury. (2) As PMNs accumulate in the inflammation site, cell- 
cell interactions mediated transcellular biosynthesis of SPMs, such as lipoxins and resolvins. (3) When resolvins and protectins are synthesized, 
they start to stimulate phagocytosis of apoptotic PMNs and cell debris by macrophages. (4) SPMs enhance macrophage uptake and the clearance 
and synthesis of lipoxins and resolvins, which inhibit inflammation through feedback mechanisms to resolve inflammation and return to tissue to 
homeostasis from local tissue injury. [Colour figure can be viewed at wileyonlinelibrary.com]
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as caspases, which inhibit apoptosis in macrophages [54, 62]. 
In general, SPMs can prevent excessive inflammation by pro-
moting macrophage survival and phagocytosis of inflamma-
tory cells and pathogens at the inflammation site [63, 64].
Adaptive immune cells
T cells
In addition to the innate immune system, adaptive immune 
cells also play a prominent role in orchestrating periodontal 
tissue damage (Figure 3). T- helper cells are activated and 
polarized into two distinct subtypes: T- helper 1 (Th1) or T- 
helper 2 (Th2) [65, 66]. Th1 cells are associated with pro- 
inflammatory processes and bone destruction, while Th2 
cells are more related to anti- inflammatory and protective 
effects [67]. Several inflammatory chronic diseases are as-
sociated with an imbalance of Th1/Th2 responses, including 
periodontal disease [68– 70]. Th1 type responses are pro-
moted by the production of inflammatory mediators (mainly 
IL- 12 and IFN- γ) by antigen- presenting cells (such as den-
dritic cells), leading to osteoclastogenesis and bone loss in 
vivo [71, 72]. Previous studies have shown that high IFN- γ 
levels in human and experimental periodontitis lesions cor-
relate with increased disease severity [73– 75]. In addition to 
the Th1 and Th2 T- cell subtypes, Th17 cells are a distinct 
subset of T cells involved in autoimmune and inflammatory 
processes, and they are characterized by IL- 17 production 
[76]. Regulatory T cells (Tregs) are another T- cell subtype 
involved in tolerance to self- antigens and the prevention of 
autoimmune disease via the production of anti- inflammatory 
cytokines, such as transforming growth factor- β (TGF- β) 
[77]. Overall, the Th1 primed T cell subsets play a major role 
in chronic inflammation and present an attractive therapeutic 
target for the treatment of chronic inflammatory diseases.
Cell culture studies focusing on the resolution of in-
flammation tend to focus exclusively on acute conditions 
mediated by the innate immune system. Therefore, little is 
known about the actions of SPMs on the cellular compo-
nents of the adaptive immune system. Besides their role in 
promoting Th1- inflammatory responses, anti- inflammatory 
dendritic cells can inhibit T- cell proliferation via the expres-
sion of indoleamine 2,3,- dioxygenase (IDO) in response 
to a combination of stimulatory factors, such as PGE2 and 
TNFα [78]. IDO is an enzyme involved in the catabolism of 
F I G U R E  3  Cytokines and periodontal disease. Bacterial challenge induces an inflammatory cytokine response. The innate immune system 
induces activation of PMNs and macrophages leading to a pro- inflammatory immune response. Moreover, the adaptive immune system contributes 
to polarization and activation of different subsets of T cells, including T- helper 2 cells, which are associated with inflammatory bone destruction 
in periodontitis and peri- implantitis. Periodontal based cells (PDLFs and GFs) are mostly responsible for inflammation and bone remodeling. 
GF, gingival fibroblasts; PDLF, periodontal ligament fibroblasts; PMN, polymorphonuclear neutrophils. [Colour figure can be viewed at 
wileyonlinelibrary.com]
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tryptophan, which produces metabolites that are cytotoxic for 
effector T cells, such as kynurenine, 3- hydroxykyrunine, and 
3- hydroxy- anthranilic acid [79]. Lipoxin has been shown to 
stimulate IDO expression in murine bone marrow- derived 
dendritic cells in vitro [80,  81]. Additionally, Resolvin E1 
(RvE1) has been shown to inhibit IL- 12 production in human 
microbially- activated dendritic cells via interactions with 
ChemR23 receptors in vitro [82]. Dendritic cells exposed to 
RvE1 have been shown to differentiate into a tolerogenic sub-
set, which is characterized by low expression levels of IL- 12 
and a high expression of IL- 10 in response to bacterial LPS 
stimulation [80]. Furthermore, lipoxin has been shown to pro-
mote the resolution of inflammation by stimulating several 
apoptotic signaling pathways in activated CD4+ T cells, such 
as IL- 1R- associated kinase (IRAK- M), IκB kinases (IKK), 
or suppressor of cytokine signaling (SOCS) [80, 81, 83]. In 
addition, lipoxin has been shown to inhibit the production 
of pro- inflammatory cytokines expression (IL- 2 and TNFα) 
by inhibiting the early growth response 1 gene (EGR1) and 
the transcriptional corepressor NGFI- A binding protein 1 
(NAB1) expression in stimulated T cells [84, 85].
B cells
B cells appear to play a prominent role in the onset and pro-
gression of chronic inflammatory and autoimmune disease 
[86]. B cells are involved in the humoral branch of immu-
nity and have been shown to accumulate at the site of oral 
infection following an immune response by innate immune 
cells (PMNs and monocytes) [87]. In progressive peri-
odontitis lesions, B cells are phenotypically characterized 
by the secretion of immunoglobulin G (IgG), IgA, and IgM 
antibodies, which are specific to periodontal bacteria (e.g., 
P. gingivalis) and one of the prominent pathological features 
of periodontitis [88]. Moreover, primed B cells have been 
shown to promote periodontal bone loss via the expression of 
several osteoclastogenic factors, such as TNFα and IL- 6 [89]. 
Furthermore, of the total amount of leukocytes that resides in 
periodontitis lesions, plasma cells accounted for 50% of cells 
and B cells accounted for approximately 20% [90, 91]. More 
importantly, the proportion of B cells in periodontal lesions 
positively correlates with disease severity [92]. Due to their 
involvement in severe periodontal disease, B cells present a 
potential therapeutic target for the treatment of periodontitis 
and peri- implantitis.
Lipoxin type A4 (LXA4) has been shown to inhibit the 
activity of memory B cell proliferation and the production 
of antibodies. Moreover, Ramon et al. [93] showed that 
LXA4 suppressed IgM and IgG antibodies in activated B 
cells in a concentration- dependent manner. In addition, 
LXA4 decreased NF- κB translocation to the nucleus, re-
sulting in the suppression of B cell activation, proliferation, 
and differentiation in vitro [93]. The inhibition of antibody 
production by memory B cells is crucial for limiting inflam-




Periodontal ligament fibroblasts (PDLFs) are connective tissue 
cells that originate from ectomesenchyme tissue of the dental 
follicle and reside in the periodontal ligament (PDL). PDLFs 
are responsible for connecting the teeth to the alveolar bone 
and are characterized by their spindle- shaped and elongated 
morphological appearance [94]. PDLFs are a specialized sub-
set of fibroblasts responsible for collagen production (e.g., type 
V collagen), wound healing, and tissue repair [95]. In addition 
to these activities, PDLFs play a crucial role in inflammation 
and alveolar bone remodeling. PDLFs promote the expression 
of pro- inflammatory cytokines and chemokines (e.g., IL- 1α, 
IL- 6, and TNFα) in response to the infiltration of microor-
ganisms (e.g., P.  gingivalis) or microbial components (e.g., 
LPS) leading to tissue- destructive responses [96, 97]. Toll- like 
receptors (TLRs) play an important role in triggering the ac-
tivation of intracellular signaling cascades in response to mi-
crobial infections. The activation of toll- like receptor 4 (TLR4) 
in response to bacterial stimulation results in the secretion of 
pro- inflammatory cytokines and chemokines via the activa-
tion of the MyD88/NF- κB intracellular signaling pathway [98]. 
Among the cytokines released during inflammation, IL- 1α is 
an important regulatory mediator of bone demineralization and 
connective tissue matrix destruction [99]. Persistent production 
of inflammatory cytokines and chemokines promote the pro-
duction of secondary inflammatory mediators (e.g., IL- 8, mac-
rophage inflammatory protein- 1α, CCL5, CC17, and CXCL13) 
that sustain the migration of PMNs, monocytes, plasma, lym-
phocytes, and mast cells to the inflammation site [100– 102]. 
In addition, inflammatory mediators produced by PDLFs in re-
sponse to bacterial stimulation can also modulate bone remod-
eling by stimulating osteoclast activity [103]. PDLFs express 
osteoclast stimulating factors (including RANKL, TNFα, and 
IL- 6) by activating intracellular signaling pathways, such as 
NF- κB and mitogen- activated protein kinases (MAPKs), that 
are associated with osteoclastogenesis and alveolar bone re-
sorption [102, 104]. To this end, PDLFs are a pharmacological 
target for the treatment of inflammation- induced bone resorp-
tion in periodontitis and peri- implantitis [96, 105].
The ability of resolvin E1 (RvE1) to restore lost periodontal 
tissues was notably demonstrated in a rabbit model of periodon-
titis by Hasturk et al. [106]. Additionally, Gaudin et al. [17] 
showed that treatment of periodontitis lesions with LXA4 pro-
moted wound healing and restored tissue homeostasis. LXA4 
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treatment correlated with the inhibition of LPS- induced produc-
tion of pro- inflammatory mediators in a dose- dependent man-
ner (e.g., IL- 1β, TNFα, and nitric oxide). Furthermore, Mustafa 
et al. [95] showed that Resolvin D1 (RvD1) treatment protected 
the periodontal ligament from chronic inflammation and pro-
moted tissue healing and regeneration in vivo by decreasing 
PGE2 production. In addition, RvD1 enhanced the proliferation 
rate of PDLFs and promoted wound closure. Based on these 
studies, PDLFs present a primary target for SPMs to promote 
periodontal regeneration and restoration of the periodontal in-
tegrity in periodontitis lesions.
Gingival fibroblasts
Gingival fibroblasts are connective tissue cells with a spindle- 
like appearance located in the gingiva apical to the gingival 
epithelium [97]. Although PDLFs and gingival fibroblasts are 
spatially located close to one another, they have distinct func-
tional activities in the repair and remodeling of periodontal tis-
sue and the adjacent alveolar bone [107]. For instance, PDLFs 
express high levels of alkaline phosphatase (ALP; an indicator 
of osteoblast functionality) and have a higher capacity for the 
formation of hard tissues compared with gingival fibroblasts 
[108,  109]. Although gingival fibroblasts also participate in 
the inflammatory process, there are distinct differences in gene 
expression between PDLFs and gingival fibroblasts [107]. 
Gingival fibroblasts are more responsive to bacterial stimu-
lation compared with PDLFs, resulting in higher expression 
levels of IL- 6 and IL- 8; this is mainly because they frequently 
encounter virulence factors based on their location in the gin-
gival epithelium [97]. In contrast, PDLFs are located closer to 
the alveolar bone compared to other cell types residing in the 
periodontium and, hence, play a more important role in bone 
remodeling. Gingival fibroblasts are also commonly associ-
ated with a higher expression of genes associated with prolif-
eration and metabolism (e.g., Cdc25B, STK15, and CDC25B), 
and hence, possess a faster proliferation capacity than PDLFs 
[107]. Due to their involvement in tissue repair and remodeling, 
gingival fibroblasts are essential targets for inducing protective 
effect by SPMs.
Human gingival fibroblasts stimulated with P.  gingiva-
lis express higher levels of pro- inflammatory cytokines and 
strong chemotactic factors for PMNs and monocytes com-
pared to their unstimulated counterparts [110]. Treatment 
of gingival fibroblasts with RvD1 has been shown to inhibit 
growth- regulated oncogene expression- α (GRO- α), which 
is a strong chemoattractant for PMNs. Additionally, RvD1 
treatment was also shown to inhibit monocyte chemoattrac-
tant protein- 1 (MCP- 1) levels, which is associated with the 
recruitment of mononuclear inflammatory cells to the site 
of infection and also positively correlates with disease se-
verity [111]. Furthermore, treatment with RvD1 increased 
the expression of TGF- β1, which mediates a wide range of 
anti- inflammatory and immunosuppressive activities, includ-
ing the inhibition of pro- inflammatory cytokines production 
(e.g., TNFα, IL- 1, and IL- 12) and the suppression of T cells, 
B cells, macrophages, and monocytes activity [112,  113]. 
Animal experiments have demonstrated that TGF- β1 knock-
out mice develop a severe inflammatory reaction and die 
within weeks of birth, suggesting that TGF- β1 is critical for 
dampening the inflammatory response and promoting wound 
healing [114]. These studies suggest that RvD1 has a poten-
tial application in wound healing and plays an important role 
in the resolution of inflammation and regeneration of gingi-
val tissue [110].
Osteoclasts
Osteoclasts are specialized bone resorptive cells respon-
sible for the degradation of mineralized bone [115]. 
Osteoclasts develop from mononucleated osteoclast pre-
cursor cells into multinucleated, tartrate- resistant acid 
phosphatase (TRAP)- positive cells in response to stimu-
latory factors expressed by osteoblasts [116]. Chronic 
infection by Gram- negative bacteria can lead to bone de-
struction due to enhanced osteoclast activity, resulting in 
alveolar bone resorption [117]. Alveolar bone resorption 
results from a homeostatic imbalance between bone for-
mation by osteoblasts and bone resorption by osteoclasts 
during periodontal infection [118]. The destructive effect 
of osteoclasts is promoted by inflammatory mediators, in-
cluding macrophage colony- stimulating factor (M- CSF), 
RANKL, TNFα, IL- 1, and PGE2 [119]. A microbial LPS 
challenge has been shown to activate pathogenic processes 
involved in bone degradation by increasing the number and 
activity of TRAP- positive osteoclasts in vivo [120]. Due to 
their involvement in bone remodeling, osteoclasts present 
an important target for the prevention of alveolar bone ero-
sion and, subsequently, tooth (or implant) loss.
Specialized pro- resolving mediators possess several im-
portant functions that can restore lost periodontal tissue, 
including bone [106]. Their role as therapeutic targets for 
the treatment of inflammation- induced bone resorption 
has previously been demonstrated in several in vitro dis-
ease models, including periodontal disease. With respect to 
bone metabolism, several studies demonstrated the ability 
of SPMs to prevent bone resorption by inhibiting gene ex-
pression. SPMs have been shown to inhibit mRNA expres-
sion of osteoclastogenesis promoting transcription factors 
(i.e., NF- κB, NFATcl and c- fos), which normally function 
to promote osteoclastic differentiation by activating the ex-
pression of osteoclast- specific genes (e.g., TRAP, cathep-
sin K, and MMP- 9) [16, 121– 123]. For instance, RvE1 has 
been shown to inhibit the expression of osteoclast- specific 
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genes by decreasing nuclear translocation of transcription 
factors from the cytoplasm to the nucleus in osteoclast 
precursor cells in vitro [124]. In addition, Liu et al. [16] 
reported that lipoxin inhibited multiple downstream path-
ways that are responsible for inflammation- induced bone 
metabolism, including the RANK signaling pathway in 
vitro. This was later shown to inhibit osteoclastogenesis 
and decrease inflammation- induced bone destruction in 
vivo [16,  120]. Furthermore, RvD1 was shown to inhibit 
osteoclast differentiation and bone resorption in vitro, and 
RANKL/M- CSF- induced bone resorption in vivo by act-
ing on RvE1 receptor chemokine- like receptor 1 (chemR23 
or CMKLR) [125– 127]. Concordantly, Van Dyke [128] 
revealed that topical administration of RvE1 three times 
per week to rabbits with periodontitis prevented bone loss 
induced by P.  gingivalis in vivo. Altogether, these stud-
ies show that SPMs can protect periodontal tissue from 
bacterial- induced activation of the inflammatory pathways 
that lead to tissue- destructive responses.
Osteoblasts
Osteoblasts are specialized bone- forming cells derived from 
mesenchymal stem cells in the bone marrow stroma respon-
sible for deposition of mineralized bone [118]. During bone 
formation (or ossification), osteoblasts mineralize secreted 
bone matrix proteins, including type I collagen and other 
various components, into hard tissue composed of hy-
droxyapatite (or bone) [129, 130]. Besides their role in bone 
remodeling, osteoblastic cells respond to bacterial stimula-
tion (e.g., to P.  gingivalis LPS) by expressing cytokines, 
prostaglandins, and growth factors (e.g., IL- 6, TNF- α, fi-
broblast growth factor), all of which mediate inflammation 
and promote osteoclastogenesis by activating the RANKL- 
production signaling pathway [131]. Additionally, the pro-
duction of inflammatory factors by osteoblasts has been 
shown to inhibit osteoblastic bone formation by upregulat-
ing RANKL production in vivo [132– 134]. Inflammation 
is responsible for bone resorption by stimulating osteoclas-
togenesis directly by actions on osteoclasts but also indi-
rectly by limiting bone formation by osteoblasts [135]. For 
these reasons, osteoblasts are an important therapeutic tar-
get to limit alveolar bone resorption.
RvE1 treatment has been shown to significantly decrease the 
IL- 6- induced NF- κB, MAPK, and p53 inflammatory signaling 
pathways in osteoblasts, which are responsible for multiple os-
teoblastic functions, including, differentiation, protein synthesis, 
and apoptosis [136]. In addition, RvE1 has been shown to de-
crease RANKL production by osteoblasts in a dose- dependent 
manner in vitro [137]. Collectively, these results suggest that 
SPMs can act directly on osteoblasts to produce a microenvi-
ronment in favor of bone perseveration and formation.
Cell- cell interactions
Cell- cell contact plays an important role in mediating 
inflammation- induced bone resorption due to increased 
gene expression of adhesion molecules and inflamma-
tory factors, which strongly promote osteoclast differen-
tiation. Cell- cell interactions between osteoclast precursor 
cells and osteoblastic cells are crucial for osteoclast dif-
ferentiation [138] (Figure 4). Contact between osteoclast 
precursor cells and osteoblastic stromal cells promotes 
osteoclast differentiation into multinucleated TRAP- 
positive osteoclasts. Bone- lining cells (e.g., PDLFs and 
gingival fibroblasts) produce high levels of alkaline 
phosphatase and have been shown to participate in bone 
formation directly via interactions with osteoclast pre-
cursor cells in vitro [139]. Moreover, osteoblasts express 
F I G U R E  4  Cell- cell interactions between osteoclast precursors 
(OPCs) and osteoclast- like cells, including periodontal ligament 
fibroblasts (PDLFs), induce the formation of multinucleated TRAP- 
positive osteoclasts in 3 key steps: (1) bacterial lipopolysaccharide 
(LPS) stimulation induces selection, attraction, and adhesion of OPCs 
(e.g., RAW264.7 cells), (2) increased inflammatory mediator signaling 
(e.g, RANKL, M- CSF and TNFα) promotes the formation of bone- 
resorbing osteoclasts, and (3) PDLFs retract and OPCs undergo further 
maturation into large multinuclear TRAP- positive osteoclasts. [Colour 
figure can be viewed at wileyonlinelibrary.com]
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osteoclastogenesis- inducing factors that act in a paracrine 
manner to influence the proliferation and differentiation of 
osteoclast precursor cells under inflammatory conditions 
[140]. In this scenario, RANKL and intracellular adhesion 
molecule (ICAM- 1) promote osteoclastic differentiation 
by binding to RANK and leukocyte function associated 
antigen- 1 receptors, respectively, on osteoclast precursor 
cells to promote osteoclastic differentiation [141– 143]. 
Furthermore, osteoblasts produce M- CSF, which binds to 
colony- stimulatory factor 1 (c- Fms) receptors on osteo-
clast precursor cells to further promote their differentiation 
towards the osteoclastic lineage [144]. The expression of 
pro- inflammatory molecules (e.g., TNFα, IL- 1β, IL- 6) by 
osteoblasts can modulate the function of osteoclast precur-
sor cells by affecting the RANKL/osteoprotegerin (OPG) 
activity [145]. Moreover, pro- inflammatory cytokines pro-
mote RANKL expression and/or decrease OPG expression 
in osteoclast precursor cells [146,  147]. Ultimately, cell- 
cell mediated osteoclastogenesis is required for the differ-
entiation of osteoclast precursor cells into multinucleated 
osteoclasts and is, therefore, a therapeutic drug target to 
alleviate inflammation- induced bone resorption.
Lipoxin (LXA4) has been shown to decrease 
inflammation- induced formation of osteoclasts in vitro 
using murine RAW264.7 in co- culture with an MC3 T3- E1 
osteoblastic cell line [18]. Li et al. [18] observed that LXA4 
inhibited polymethylmethacrylate (PMMA)- upregulated 
production of TNFα, IL- 1β, PGE2, and granulocyte- 
macrophage colony- stimulating factor (GM- CSF) in a 
dose- dependent manner. Furthermore, LXA4 counteracted 
RANKL/LPS- induced formation and function of osteo-
clasts in an in vitro co- culture model composed of primary 
human PDLFs and murine RAW246.7 cell line [123]. 
LXA4 suppressed RANKL/LPS- induced upregulation of 
osteoclast- associated genes (e.g., RANKL, TRAP, cathep-
sin K), TRAP activity, and the number of TRAP- positive 
cells. Collectively, these studies suggest that SPMs can be 
used to inhibit inflammation- induced bone resorption by 
minimizing cell- cell interactions between osteoclast pre-
cursor cells and osteoblastic cells.
CONCLUSION AND FUTURE 
PERSPECTIVES
The inflammatory response is a protective process designed 
to eliminate harmful stimuli and promote the resolution of 
inflammation. In the past, it was generally held that inflam-
matory resolution was a passive event. However, evidence 
from studies carried out during the last decades has shown 
that it is a coordinated active process mediated by a variety 
of SPMs. Exogenous SPMs, such as lipoxins and resolvins, 
restore tissue homeostasis by inhibiting leukocyte infiltration 
and cytokine/chemokine generation. More specifically, SPMs 
induce apoptosis in PMNs and promote their removal by 
macrophages. More importantly, exogenous SPMs can be 
used to reverse inflammation in periodontal and peri- implant 
disease and return inflamed tissue to homeostasis. A thorough 
understanding of the resolution pathways can help to develop 
a more “personalized” treatment option rather than prescrib-
ing one treatment to suit all patients regardless of the causa-
tive factor. When viewed in the context of SPMs’ ability to 
reduce tissue injury in experimental models of inflammation, 
SPMs can be used to promote resolution pathways and restore 
tissue homeostasis. A growing body of in vitro and in vivo 
research suggests modulation of the inflammatory response 
in several cell types that contribute to the resolution of peri-
odontal inflammation. However, further studies are needed 
to elucidate the legitimacy of SPMs as a candidate for peri-
odontal therapy. Overall, SPMs warrant further study on the 
beneficial effect of these agents in periodontal treatment.
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